• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Lyra Therapeutics, Inc. (LYRA) Stock Price, News & Analysis

Lyra Therapeutics, Inc. (LYRA) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.18

-$0

(2.08%)

Day's range
$0.17
Day's range
$0.19
50-day range
$0.1625
Day's range
$0.3079
  • Country: US
  • ISIN: US55234L1052
52 wk range
$0.16
Day's range
$6.79
  • CEO: Dr. Maria Palasis Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -9.08
  • Piotroski Score 3.00
  • Grade Neutral
  • Symbol (LYRA)
  • Company Lyra Therapeutics, Inc.
  • Price $0.18
  • Changes Percentage (2.08%)
  • Change -$0
  • Day Low $0.17
  • Day High $0.19
  • Year High $6.79

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/05/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.50
  • High Stock Price Target $0.50
  • Low Stock Price Target $0.50
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.17
  • Trailing P/E Ratio -0.27
  • Forward P/E Ratio -0.27
  • P/E Growth -0.27
  • Net Income $-62,680,000

Income Statement

Quarterly

Annual

Latest News of LYRA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

  • Top transfers: Lyra Drive business sells for $10 million

    Top property transfers in Franklin, Delaware, Fairfield, and Licking counties from July 15-19 include sales like $3.83M in Gahanna, $2.38M in Columbus, and $1.8M in Columbus. Other notable transaction...

    By Yahoo! Finance | 3 months ago
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Lyra Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of LYRA in the last quarter?

    In the last quarter Lyra Therapeutics, Inc. earnings were on Wednesday, August, 14th. The Lyra Therapeutics, Inc. maker reported -$0.29 EPS for the quarter, beating analysts' consensus estimates of -$0.34 by $0.05.

  • What is the Lyra Therapeutics, Inc. stock price today?

    Today's price of Lyra Therapeutics, Inc. is $0.18 — it has decreased by 2.08% in the past 24 hours. Watch Lyra Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Lyra Therapeutics, Inc. release reports?

    Yes, you can track Lyra Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Lyra Therapeutics, Inc. stock forecast?

    Watch the Lyra Therapeutics, Inc. chart and read a more detailed Lyra Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Lyra Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Lyra Therapeutics, Inc. stock ticker.

  • How to buy Lyra Therapeutics, Inc. stocks?

    Like other stocks, LYRA shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Lyra Therapeutics, Inc.'s EBITDA?

    Lyra Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Lyra Therapeutics, Inc.’s financial statements.

  • What is the Lyra Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -40.2310654685, which equates to approximately -4,023.11%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Lyra Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Lyra Therapeutics, Inc.'s financials relevant news, and technical analysis. Lyra Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Lyra Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Lyra Therapeutics, Inc.’s technical analysis.

  • A revenue figure for Lyra Therapeutics, Inc. for its last quarter?

    Lyra Therapeutics, Inc. published it's last quarterly revenues at $195,000.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.